[Combination chemotherapy in Hodgkin's disease].
D000293:Adolescent; D000328:Adult; D000368:Aged; D001855:Bone Marrow Diseases / Q000139:chemically induced; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009150:Mustard Compounds / Q000009:adverse effects; D010292:Paresthesia / Q000139:chemically induced; D011239:Prednisolone / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D011379:Prognosis; D012075:Remission, Spontaneous; D013924:Thrombophlebitis / Q000139:chemically induced; D014747:Vinblastine / Q000009:adverse effects / Q000627:therapeutic use; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D009150:Mustard Compounds; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D011239:Prednisolone
Kombinationskemoterapi vid Mb Hodgkin.